Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 8;68(10):e0106424.
doi: 10.1128/aac.01064-24. Epub 2024 Aug 29.

Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers

Naoyuki Miyashita  1 , Yasushi Nakamori  2 , Makoto Ogata  1 , Naoki Fukuda  1 , Akihisa Yamura  1 , Tomoki Ito  1
Affiliations

Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers

Naoyuki Miyashita et al. Antimicrob Agents Chemother. .

Abstract

We evaluated the efficacy of ensitrelvir for the treatment of cough due to coronavirus disease 2019 Omicron variant in medical healthcare workers. A total of 633 patients were registered in this study: 206 patients chose ensitrelvir and 427 patients chose symptomatic treatment. Difference in score changes using the Leicester Cough Questionnaire between groups was 3.17 on day 4, 3.24 on day 7, and 2.46 on day 14. The analysis demonstrated a significant difference at all time points.

Keywords: COVID-19; Omicron variant; SARS-CoV-2; cough symptom; ensitrelvir.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y. 2022. Discovery of S-217622, a non-covalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem 65:6499–6512. doi:10.1021/acs.jmedchem.2c00117 - DOI - PMC - PubMed
    1. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, et al. . 2022. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nat New Biol 607:119–127. doi:10.1038/s41586-022-04856-1 - DOI - PMC - PubMed
    1. He J, Hu L, Huang X, Wang C, Zhang Z, Wang Y, Zhang D, Ye W. 2020. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: insights from structures of protease and inhibitors. Int J Antimicrob Agents 56:106055. doi:10.1016/j.ijantimicag.2020.106055 - DOI - PMC - PubMed
    1. Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Fukuhara T, Ichihashi G, Sanaki T, Baba K, Takeda Y, Tsuge Y, Uehara T. 2022. A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob Agents Chemother 66:e0069722. doi:10.1128/aac.00697-22 - DOI - PMC - PubMed
    1. Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T. 2023. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin Infect Dis 76:1403–1411. doi:10.1093/cid/ciac933 - DOI - PMC - PubMed

Supplementary concepts

LinkOut - more resources